1. American Congress of Obstetricians and Gynecologists. Uterine Fibroids.
  2. American Society for Laser Medicine and Surgery. General Surgery. Accessed at
  3. American Society for Reproductive Medicine:
  4. Infertility in Practice, 3rd ed.; Balen AH. Informa Healthcare, 2008; London UK.
  5. BC Cancer Agency. Accessed at
  6. Boston Handbook of Infertility, 2nd ed.; Bayer SR, Alper MM, Penzias AS editors. Informa Healthcare 2007; London UK.
  7. Brassard, M et al. Basic infertility including polycystic ovary syndrome. Med Clin N Am 2008;(92):1163-1192.
  8. Bravelle® Product Monograph. Ferring Canada Inc. 2008.
  9. Brenner and Rector’s The Kidney 8th ed.; Brenner BM editor. Saunders Elsevier 2007; Philadelphia PA.
  10. Burns LH. Psychiatric aspects of infertility and infertility treatments. Psychiatr Clin N Am 2007;(30):689-716.
  11. Burry KA. Reproductive medicine: Where we have been, where we are, where are we going? An ethical perspective. Am J Obstet Gynecol; 2007 Meeting Papers: 578-580.
  12. Canadian Fertility and Andrology Society (CFAS). Human assisted reproduction 2009 live birth rates for Canada. Press release, December 3, 2009. Accessed at
  13. Centres for Disease Control and Prevention. 2006 Assisted Reproductive Technology (ART) Report: Section 2—ART cycles using fresh, nondonor eggs or embryos. Accessed at
  14. Case AM. Infertility evaluation and management: Strategies for family physicians. Can Fam Physician 2003;49:1465–1472.
  15. Caperton L et al. Assisted reproductive technologies do not alter mutation frequency or spectrum. PNAS 2007;104(12):5085–5090.
  16. Campbell-Walsh Urology, 9th ed.; Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA editors. W. B. Saunders 2007; Philadelphia PA.
  17. Carp HJA et al. Autoantibodies as predictors of pregnancy complications. Rheumatology 2008;47:iii6–iii8.
  18. Cecil Medicine, 23rd ed.; Goldman L, Ausiello D editors. Saunders Elsevier 2007; Philadelphia PA.
  19. Centers for Disease Control and Prevention. Report to Congress: Infertility and prevention of sexually transmitted diseases, 2000-2003., November 2004.
  20. Cetrotide® Product Monograph. Serono Canada Inc. July 23, 2003.
  21. Chasan-Taber L et al. Oral contraceptives and ovulatory causes of delayed fertility. Am J Epidemiol 1997; 146(3):258-265.
  22. Clinical Gynecologic Endocrinology and Infertility, 7th ed.; Speroff L, Fritz MA editors. Lippincott Williams and Wilkins, 2005; Philadelphia PA.
  23. Chlamydia. July, 2004. Health Canada Catalogue # 0-662-37624-2.
  24. Clomid® Product Monograph. Sanofi-Aventis Canada Inc. 2009.
  25. Comprehensive Gynecology, 5th ed.; Katz VL, Lentz GM, Lobo RA, Gershenson DM editors. Mosby Elsevier 2007; Philadelphia PA.
  26. Confino E et al. Transcervical balloon tuboplasty: A multicenter study. JAMA 1990;264(16):2079-2082.
  27. Conn's Current Therapy, 60th ed. Rakel RE, Bope ET editors. Saunders Elsevier, 2008; Philadelphia, PA.
  28. CrinoneTM Product Monograph. EMD Serono Canada Inc. May 14, 2008.
  29. Dankert T et al. A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility. Human Reprod 2007;22(3):792-797.
  30. Depo-Provera® Product Monograph. Pfizer Canada Inc. November 18, 2010.
  31. Dorlands Medical Dictionary. Accessed at
  32. Deschaud H, Daures J, Hedon B. Prospective evaluation of falloposcopy. Human Reprod 1998;13(7):1815–1818.
  33. Editors. The nulliparous patient, the IUD, and subsequent fertility Br Med J 1978 Jul 22;2(6132):233.
  34. E-medicine: Accessed at
  35. Endocrinology: An Integrated Approach. Nussey SS, Whitehead SA. Oxford: BIOS Scientific Publishers; 2001.
  36. Endometrin® Product Monograph. Ferring Canada Inc. September 30, 2009.
  37. European Society of Human Reproduction and Embryology (ESHRE). Good clinical treatment in assisted reproduction: and ESHRE position paper. June 2008. Accessed at
  38. Evra® Product Monograph. Janssen-Ortho Inc. March 16, 2010.
  39. Expert Panel on Infertility and Adoption. Raising expectations: Recommendations of the Expert Panel on Infertility and Adoption. Ontario Ministry of Health and Long-term Care, 2009.
  40. Ferri's Clinical Advisor 2010, 1st ed.; Ferri, FF et al. editors. Mosby Elsevier, 2010; Philadelphia, PA.
  41. Gleicher N et al. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Eng J Med 2000;343(1):1–7.
  42. Gonal-f® Pen Product Monograph. EMD Serono Canada Inc. 2007.
  43. Grainger DA et al. Preconception care and treatment with assisted reproductive technologies. Matern Child Health J 2006;10:S161–S164.
  44. Government of Canada.. Bill C-6. Accessed at
  45. Gunby J et al. Assisted reproductive technologies in Canada: 2007 results from the Canadian ART register. Fertil Steril 2010; (July) E-pub ahead of print.
  46. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. 4th ed.; Shannon MW, Borron SW, Burns MJ editors. Saunders Elsevier, 2007; Philadelphia, PA.
  47. Hammer-Burns L. Psychiatric aspects of infertility and infertility treatments. Psychiatr Clin N Am 2007;30:689–716.
  48. Handbook of the Assisted Reproduction Laboratory. Keel, BA et al. editors. CRC Press LLC, 2000; Boca Raton, FL.
  49. HealthLinkBC. Accessed at
  50. Henry's Clinical Diagnosis and Management by Laboratory Methods, 21st ed.; McPherson RA, Pincus MR editors. W.B. Saunders 2006; Philadelphia PA.
  51. Hess RA. Estrogen in the adult male reproductive tract: A review. Reprod Biol Endocrinol 2003;1:52.
  52. Hughes E. Access to effective fertility care in Canada. J Obstet Gynaecol Can 2008;30(5):389–390.
  53. Infectious Diseases, 2nd ed.; Cohen J, Powderly WD editors. Mosby Elsevier, 2004; Philadelphia PA.
  54. Janssen HJG et al. Antisperm antibodies and in vitro fertilization. J Assist Reprod Genet 1992;9(4):345–349.
  55. Joint SOGC-CFAS Guideline. Pregnancy outcomes after assisted reproductive technology. J Obstet Gynaecol Can 2006;28(3):220–233.
  56. Katz M et al. Hormonal Effects of Wedge Resection of Polycystic Ovaries. Obstet Gynecol 1978;51(4):437-444.
  57. Lab Tests Online. Accessed at
  58. Lupron® Product Monograph. Abbott Laboratories Ltd. March 23, 2010.
  59. Luveris® Product Monograph. EMD Serono Canada Inc. 2009.
  60. McCallum TJ et al. Fertility in men with cystic fibrosis: An update on current surgical practices and outcomes. CHEST 2000;118(4):1059–1062.
  61. Min JK et al. Guidelines for the number of embryos to transfer following in vitro fertilization. JOGC 2006;182:799-813.
  62. Mol BW and van Wely M. Risk of preterm birth is increased in IVF compared to spontaneously conceived twins - meta-analysis. Obstet Gynecol 2006;8(1):46-47.
  63. Menopur® Product Monograph. Ferring Canada Inc. 2008.
  64. Nader S. Adrenarche and polycystic ovary syndrome: A tale of two hypotheses. J Pediatr Adolesc Gynecol 2007;20:353-360.
  65. National Cancer Institute. DES: Questions and Answers. Accessed at
  66. National Institute for Clinical Excellence, National Collaborating Centre for Women’s and Children’s Health: Clinical Guideline 2004. RCOG Press at the Royal College of Obstetricians and Gynaecologists.
  67. National Institute of Allergy and Infectious Diseases. Pelvic inflammatory disease. National Institutes of Health. U.S. Department of Health and Human Servies. Accessed at
  68. National Library of Medicine, National Institute of Health accessed at
  69. Nelson Textbook of Pediatrics. 18th ed.; Kliegman RM, Behrman RE, Jenson HB, Stanton BF editors. Saunders Elsevier 2007; Philadelphia, PA.
  70. Nikolaou D et al. Hirsutism. Curr Obstet Gynaecol 2005;15(3):174-182
  71. NuvaRing® Product Monograph. Schering-Plough Canada Inc. February 19, 2009.
  72. Obstetrics and Gynecology, 6th ed.; Beckmann CRB et al. editors. Lippincott Williams & Wilkins, 2010; Philadelphia PA.
  73. Obstetrics: Normal and Problem Pregnancies, 5th ed.; Gabbe S, Niebyl J, Simpson J editors. Churchill Livingstone Elsevier, 2007; Philadelphia, PA.
  74. Orgalutran® Product Monograph. Schering-Plough Canada Inc. September 1, 2010.
  75. Orphanet encyclopedia. Accessed at
  76. Ovidrel® Product Monograph. EMD Serono Canada Inc. 2009.
  77. Ontario Health Technology Advisory Committee. In vitro fertilization and multifetal pregnancy: Health technology policy assessment. Ontario Ministry of Health and Long-term Care, 2006.
  78. Oxford handbook of Reproductive Medicine & Family Planning; McVeigh E, Homburg R, Guillebaud J. Oxford University Press, 2008; New York, NY.
  79. Rosen’s Emergency Medicine: Concepts and Clinical Practice, 6th ed.; Marx JA et al. editors; Mosby Elsevier, 2006; Philadelphia, PA.
  80. Patil M. Assessing tubal damage. J Hum Reprod Sci 2009;2(1):2–11.
  81. Pauli SI et al. Current status of the approach to assisted reproduction. Pediatr Clin N Am 2009;56:467–488.
  82. Practice Committee of the American Society of Reproductive Medicine (ASRM). Intracytoplasmic sperm injection (ICSI). Fertil Steril 2008;90:S187.
  83. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril 2006;86(Suppl 4):S187–S193.
  84. Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: A technical bulletin. Fertil Steril 2008;90(Suppl 3):S7–S12.
  85. Practice Committee of the American Society for Reproductive Medicine. Vasectomy reversal. Fertil Steril 2008;90(3):S78-S82.
  86. Pray JJ and Pray WS. Ovulation and fertility home diagnostic kits. October 8, 2003. Accessed at
  87. Pregnyl® Product Monograph. Schering-Plough Canada Inc. October 13, 2010.
  88. Public Health Agency of Canada. Brief report on sexually transmitted infections in Canada: 2007. Accessed at
  89. Public Health Agency of Canada. Reported cases of notifiable STI from January 1 to June 30, 2009 and January 1 to June 30, 2010 and corresponding annual rates for the years 2009 and 2010. Accessed at
  90. Puregon® Product Monograph. Schering-Plough Canada Inc. 2009.
  91. Repronex® Product Monograph Ferring Canada Inc. 2008.
  92. RESOLVE: The National Infertility Association. Accessed at
  93. Reilly DR. Surrogate pregnancy: A guide for Canadian prenatal health care providers. CMAJ 2007;176(4):483-485.
  94. Ridenour AF et al. The infertility resilience model: Assessing individual, couple, and external predictive factors. Contemp Fam Ther 2009;31:34–51.
  95. Robbins and Cotran Pathologic Basis of Disease, Professional Edition, 8th ed.; Kumar V, Abbas AK, Fausto N, Aster JC editors. Saunders Elsevier, 2009; Philadelphia, PA.
  96. Esteves SC, Schneider DT, Verza Jr. S. Influence of antisperm antibodies in the semen on intracytoplasmic sperm injection outcome. Int Braz J Urol 2007 Nov-Dec;33(6):795-802.
  97. Saravelos SH et al. Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: A critical appraisal. Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. June 6, 2008.
  98. Sermon K, Michiels A, Harton G. ESHRE PGD Consortium data collection VI: Cycles from January to December 2003 with pregnancy follow-up to October 2004. Human Reprod 2007;22(2):323–336.
  99. Society for Assisted Reproductive Technology (SART). Preparing for ART: Emotional considerations. Accessed at
  100. Sunderam S et al. Assisted Reproductive Technology Surveillance – United States, 2006. National Center for Chronic Disease Prevention and Health Promotion 2009;58(SS05);1-25.
  101. Serophene® Product Monograph. EMD Serono Canada Inc. 2007.
  102. Statistics Canada, Health Statistics Division. Births 2006. Catalogue no. 84F0210X. Ministry of Industry, 2008.
  103. Sex facts in Canada 2006. Accessed at
  104. Sueoka K, Asada H, Tsuchiya S, Kobayashi N et al. Falloposcopic tuboplasty for bilateral tubal occlusion. A novel infertility treatment as an alternative for in-vitro fertilization? Human Reprod 1998;13(1):71–74.
  105. Suprefact® Product Monograph. Sanofi-Aventis Canada Inc. August 10, 2010.
  106. Synthroid® Product Monograph. Abbott Laboratories Ltd. May 25, 2010.
  107. Taylor E, Gomel V. The uterus and fertility. Fertil Steril 2008;89(1):1–16.
  108. Textbook of Family Medicine. 7th ed.; Rakel RE editor. Saunders Elsevier, 2007; Philadelphia, PA.
  109. Textbook of In Vitro Fertilization and Assisted Reproduction. 3rd ed.; Brinsden PR editor. Informa Healthcare, 2007; Cambridge, UK.
  110. The Biology of the Skin; Frienkel, Ruth K. and Woodley, David T editors. The Parthenon Publishing Group, 2001; Pearl River, NY.
  111. The International Council on Infertility Information Dissemination, Inc. Glossary Accessed at
  112. The Mayo Clinic. Health Information. Accessed at
  113. The New Harvard Guide to Women’s Health; Carlson KJ et al. Harvard University Press, 2004; Cambridge, MA.
  114. Tri-Cyclen Lo® Product Monograph. Janssen-Ortho Inc. January 25, 2006.
  115. U.S. Department of Health and Human Services. Office on Women’s Health. Infertility. U.S. Department of Health and Human Services, 2009.
  116. U.S. National Institutes of Health, National Cancer Institute SEER Training Modules: Anatomy and physiology: Reproductive system. Accessed at
  117. Uterine Artery Embolization and Gynecologic Embolotherapy; Spies JS, Pelage J editors. Lippincott Williams & Wilkins, 2005; Philadelphia PA.
  118. Van Loenen ACD et al. GnRH agonists, antagonists, and assisted conception. Semin Reprod Med 2002;20(4):349-64.
  119. Wagenaar K et al. An overview of studies on early development, cognition, and psychosocial well-being in children born after in vitro fertilization. J Dev Behav Pediatr 2008;29(3);219-230.
  120. Williams Textbook of Endocrinology, 11th ed.; Kronenberg HM, Melmed S, Polonski KS, Larsen PR editors. Saunders Elsevier, 2008; Philadelphia PA.
  121. Wong AYK, Walker SM. Falloposcopy – a prerequisite to the proper assessment of tubal infertility. HKMJ 1999;5:76-81.
  122. Zuber T. Endometrial biopsy. Am Fam Phys 2001;63(6):1131–1135.

Clinic Locator